Drug Trial Radar · NCT05638776
Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Dec 6, 2022
Primary completion
Jul 9, 2025
Study completion Jul 9, 2025
Sponsor
- Lead sponsor
- Regend TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- The First Affiliated Hospital of Guangzhou Medical University; Southwest Hospital, China; Shanghai Zhongshan Hospital; China-Japan Friendship Hospital; Shanghai East Hospital; Regend Therapeutics XLotus (Jiangxi) Co, Ltd.; The First Affiliated Hospital of Nanchang University; Xiangya Hospital of Central South University; The First Affiliated Hospital of Soochow University
- First posted
- Dec 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow. In a large number of patients, diffusion function is impaired along with the progression of disease. REGEND001 cell therapy, comprised of airway basal cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, single-blind, placebo-parallel-controlled trial is performed to assess the efficacy and safety of REGEND001 cell therapy in treatment of chronic obstructive pulmonary disease with diffusion capacity defect.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
REGEND001 cell therapyDrug
Transplantation of the cell product
PlaceboDrug
Transplantation of Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responsive rate (RR)Time frame: 12 weeks after treatment, 24 weeks after treatment
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
The Southwest Hospital of AMU
Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Xiangya Hospital of Central South University
Changsha, Hunan, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Zhongshan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.